HuidaGene Therapeutics, a China-based clinical-stage genome-editing company, announced on Wednesday that it has named gene therapy industry veteran, Alvin Luk, PhD, MBA, CCRA, as its co-founder, member of the board of directors and chief executive officer.
Dr Luk has more than 30 years of experience in global drug development, gene/cell therapy medicines, biological drugs, and rare diseases, and participated in 21 approved products at different biotech/biopharma companies, including Spark Therapeutics, Biogen, Bayer HealthCare, Shanghai Henlius, amongst others.
Hui Yang, Ph.D., co-founder, chief scientific advisor, and chairman of the scientific advisory board (SAB) at HuidaGene, said, 'With more than a 30-year career in biotech/biopharma industry, we're delighted to appoint an industry veteran of Alvin's calibre as the company's co-founder and CEO. As more of our innovative medicines progress toward clinical development, Alvin's significant global drug development experience, proven leadership, passion for genetic medicine, and focus on bringing novel modalities to patients globally add tremendous values to HuidaGene. As we enter the next phase, our mission of 'answering the patients' remains the same. My team and I look forward to working closely with Alvin to ensure continuity, build on the progress HuidaGene made, and deliver value to our stakeholders.'
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration